Major advances have been made in precision medicine of breast cancer patients with a series of molecular targeted therapies now in clinical use or in late clinical development. These new therapeutic measures need to be integrated with local treatments, particularly with radiation therapy in both curative and advanced settings. Although a synergistic effect could be obtained between targeted therapies and irradiation, potential safety concerns should be carefully considered. At present, scarce evidence exists due to a lack of quality assurance on radiation therapy in pivotal trials of new drugs and missing reports on safety in case of concurrent radiation therapy, commonly administered with heterogenous doses and fractionations, especially in advanced disease. A major contribution for effectively combining radiation and targeted therapies in breast cancer could derive from clinically relevant preclinical studies. This review integrates preclinical and clinical evidence on how targeted agents and radiation therapy could be combined to help physicians in their daily clinical practice and to improve the clinical management of patients.

Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside / Meattini, Icro; Livi, Lorenzo; Lorito, Nicla; Becherini, Carlotta; Bacci, Marina; Visani, Luca; Fozza, Alessandra; Belgioia, Liliana; Loi, Mauro; Mangoni, Monica; Lambertini, Matteo; Morandi, Andrea. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - ELETTRONICO. - 108:(2022), pp. 0-0. [10.1016/j.ctrv.2022.102417]

Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside

Meattini, Icro;Lorito, Nicla;Becherini, Carlotta;Bacci, Marina;Visani, Luca;Loi, Mauro;Mangoni, Monica;Morandi, Andrea
2022

Abstract

Major advances have been made in precision medicine of breast cancer patients with a series of molecular targeted therapies now in clinical use or in late clinical development. These new therapeutic measures need to be integrated with local treatments, particularly with radiation therapy in both curative and advanced settings. Although a synergistic effect could be obtained between targeted therapies and irradiation, potential safety concerns should be carefully considered. At present, scarce evidence exists due to a lack of quality assurance on radiation therapy in pivotal trials of new drugs and missing reports on safety in case of concurrent radiation therapy, commonly administered with heterogenous doses and fractionations, especially in advanced disease. A major contribution for effectively combining radiation and targeted therapies in breast cancer could derive from clinically relevant preclinical studies. This review integrates preclinical and clinical evidence on how targeted agents and radiation therapy could be combined to help physicians in their daily clinical practice and to improve the clinical management of patients.
108
0
0
Meattini, Icro; Livi, Lorenzo; Lorito, Nicla; Becherini, Carlotta; Bacci, Marina; Visani, Luca; Fozza, Alessandra; Belgioia, Liliana; Loi, Mauro; Mangoni, Monica; Lambertini, Matteo; Morandi, Andrea
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0305737222000810-main.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: DRM non definito
Dimensione 1.32 MB
Formato Adobe PDF
1.32 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2158/1278580
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact